Avian reoviridae and vaccines thereof
AssigneeBiomune Company
InventorsKristi Mae Dorsey, John Konx Rosenberger, Sandra Cloud Rosenberger
Life of this patent
Estimating the term…
Abstract
This invention relates to novel unique strains avian reoviridae that were isolated from severe cases of Runting Stunting Syndrome. The present invention also relates to the isolation and uses of novel unique avian reoviridae, diagnostic assays using nucleotide or amino acid specific components of such viruses, such as the sequence encoding Sigma C capsid protein and to vaccines that protect birds from diseases caused by such viruses.
Claims18
A vaccine comprising a peptide encoded by SEQ ID NO:
- 1 or 2 and an adjuvant selected from aluminum hydroxide, aluminum phosphate, aluminum oxide, an oil-in-water or a water-in-oil emulsion.
An inactivated avian reoviridae produced by contacting an avian reoviridae deposited at the ATCC under accession number PTA-9301, PTA-9302 or PTA-9297 with formaldehyde, beta-propriolactone or ethylene-imine and inactivating said avian reoviridae.
An attenuated avian reoviridae produced by attenuation of an avian reoviridae deposited at the ATCC under accession number PTA-9301, PTA-9302 or PTA-9297, said attenuation comprising inoculating a primary cell culture with an avian reoviridae deposited at the ATCC under accession number PTA-9301, PTA-9302 or PTA-9297, or passaging said avian reoviridae on said cell culture until a cytopathic effect is obtained, and subsequent freezing, thawing and isolation of said attenuated reoviridae.
Dependencies are inferred from the claim text.